Analytical Data
-
Gene name
APOLD1
- Application
-
Alternative Names
Vascular early response gene protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96LR9
-
Expression Region
1-279aa
-
Molecular Weight
33.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APOLD1, or Apolipoprotein L Domain Containing 1, is a protein that has garnered significant interest in the field of biomedical research due to its potential roles in various physiological and pathological processes. Initially identified in the context of lipoprotein metabolism and vascular biology, APOLD1 is believed to be involved in regulating endothelial function and maintaining the integrity of the blood-brain barrier. Recent studies have suggested its involvement in inflammatory responses, neuroprotection, and even tumor biology, indicating that APOLD1 may have broader implications in disease states such as cancer and neurodegenerative disorders. The exploration of recombinant APOLD1 protein has become a focal point for researchers aiming to elucidate its biological functions and therapeutic potential. By generating and characterizing recombinant APOLD1, scientists are investigating its structure-function relationships, signaling pathways, and interactions with various cellular components. Understanding these mechanisms could pave the way for novel therapeutic strategies that leverage APOLD1's properties to enhance vascular health, target inflammation, or improve outcomes in neurological diseases. As research progresses, the recombinant form of APOLD1 stands to provide invaluable insights into not only its physiological roles but also its potential exploitation in clinical applications, making it a critical subject of ongoing investigation in molecular and cellular biology.
